Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
about
Interpretation of cytogenetic results in multiple myeloma for clinical practiceAdvances in understanding prognosis in myeloma.Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Multiple myeloma in the marrow: pathogenesis and treatments.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Risk Stratification in Multiple Myeloma.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.Genomic Aberrations in Multiple Myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
P2860
Q26777803-C84D7C09-43E0-4E42-88FD-2D9BC5FE5F13Q30244061-5468DADE-3296-432A-97CB-64F8B571ECF7Q36382187-513A7D63-D41D-4A40-A0CF-699926AC3B51Q36725401-3F4ED39D-345C-48A2-9C75-5092C299751DQ37037265-3482F096-46DF-47DB-BB62-C2597AA30FCFQ38736249-D5ECFBE9-A8E5-4932-9122-9EECEEFB707DQ38778519-56358D45-5107-4B6B-8E35-CF3088864CA4Q38915277-5DDF71FB-CAA8-48A9-A354-D6B8B933392DQ38970573-1C1470AD-4669-4869-AD5B-9109E1A0D4C2Q38979403-BBA6AF0D-B773-4F63-A691-69F4153B9CE1Q39788992-076C8555-C5E0-4A2C-BFC0-F18445462557Q40533502-F0513401-637C-4A10-97A6-03D1F77D3E05Q48187249-5649113A-1D27-47C4-BCC6-9449EA8DBDA3Q50040054-EAC12F76-B713-4FD9-81A7-5CD821D70C41Q50057730-EE4DEB80-7D5B-4B9F-863C-15744C0EA73F
P2860
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Coexistent hyperdiploidy does ...... may precede IGH translocations
@ast
Coexistent hyperdiploidy does ...... may precede IGH translocations
@en
type
label
Coexistent hyperdiploidy does ...... may precede IGH translocations
@ast
Coexistent hyperdiploidy does ...... may precede IGH translocations
@en
prefLabel
Coexistent hyperdiploidy does ...... may precede IGH translocations
@ast
Coexistent hyperdiploidy does ...... may precede IGH translocations
@en
P2093
P2860
P50
P1433
P1476
Coexistent hyperdiploidy does ...... may precede IGH translocations
@en
P2093
Alex Murison
Dil B Begum
Faith E Davies
Fiona M Ross
Graham H Jackson
Lorenzo Melchor
Mark T Drayson
Martin F Kaiser
Nasrin B Dahir
Paula Proszek
P2860
P304
P356
10.1182/BLOOD-2014-07-584268
P407
P577
2014-11-26T00:00:00Z